(OTCPK:RGBP) Regen BioPharma, Inc.
Regen (OTCQB:RGBP) has come a long way since 2014. They now seem to be on the the path of a potential to merge or to be bought out by a Big Pharma.
Two small RGBP like companies were purchased by Big Pharma in the past year for Billions. It's said they were six months to a year ahead of RGBP in their similar/like programs such as RGBP's NR2F6.
Eli Lilly, Inc. (NYSE:LLY) entered into an agreement with RGBP some time ago. Why would a giant like (LLY) work with RGBP if they didn’t see the value? The future? Could (LLY) have RGBP in their crosshairs? Who knows.
No, this isn't going to happen overnight, but the possibility is eventually one day, it may just happen overnight. Someone like a (LLY), Merc, Bristol Myers Squibb will come forward with an offer. Time will tell.
It may be that the new Business Advisory Board (NYSEARCA:BAB) was created and key appointments announced for that purpose (merge/buyout), or to ready the company when they are near or in a position to take a new drug to market. A former executive from Eli Lilly and two current CVS Health board members have joined the (BAB).
RGBP has a solid structure, platform, for a successful future. Patience is a virtue, and necessary for a company such as this. We think it is a good long pay, yet for those not as patient, the potential for short term gain/profit does exist and has been evident in its history. RGBP at times has presented just that opportunity, 10%, 25% 100%, and even near 400% bounces.
With already Two (2) FDA Approved IND #'s for New Drugs, HemaXellerate and dCellVax. They also discovered HemaXellerate has been successful in treating a most painful side effect of Chemo-Therapy, Bone Marrow Suppression in trials.
The company is now focused on rapidly advancing novel technologies through Pre-Clinical, and Phase I/ II clinical trials for immunology and immunotherapy spaces. The NR2F6 Program at Regen aims to identify antagonists of NR2F6 to unleash the cancer-killing potential of a patient’s own immune system, as well as identifying agonists which should suppress the immune system in diseases where the immune system is over activated, such as autoimmunity.
RGBP is believed to be one of nine with NR2F6 Programs and may be the only in the Small Molecule Therapies space/field. Biotechnology-stem cell and immunotherapies for specialty niche treatments for immuno-oncology, stem cell/cancer stem cell, gene silencing. Three products in development based on the newly discovered cancer stem cell gene target.
While the company focuses on small molecule therapies for cancer and autoimmune diseases/disorders, they are ever so close to achieving that important milestone that leads to the next phase of drug development.
Is it time to take a better look? Stop passing by RGBP? We think so. If you do you can refer to:
Regen BioPharma's website above or:
When Press Releases/News/Filings are announced, you can have it directly delivered to your email by visiting: https://www.smallcapsolutions.com and subscribing to our email. You will not be inundated with junk. Only pertinent news, etc. will be sent to you.
Robert E. Kreh – Principal
Small Cap Solutions, LLC
(OTCQB:RGBP) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.